Article(id=1330127216941314265, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330127189372153867, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2018.02.014, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1510156800000, receivedDateStr=2017-11-09, revisedDate=1513353600000, revisedDateStr=2017-12-16, acceptedDate=null, acceptedDateStr=null, onlineDate=1795056641086, onlineDateStr=2026-11-19, pubDate=1518192000000, pubDateStr=2018-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795056641086, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795056641086, creator=13701087609, updateTime=1795056641086, updator=13701087609, issue=Issue{id=1330127189372153867, tenantId=1146029695717560320, journalId=1319690329412173987, year='2018', volume='39', issue='2', pageStart='S9', pageEnd='144', issueExtLink='null', onlineDate='null', pubDate='1518192000000', pubDateStr='2018-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795056634514, creator='13701087609', updateTime=1795056680728, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330127383656510048, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330127189372153867, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330127383656510049, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330127189372153867, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=S9, endPage=S13, ext={EN=ArticleExt(id=1330127217109086426, articleId=1330127216941314265, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress of panobinostat on multiple myeloma treatment, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Multiple myeloma (MM) is a common malignant blood tumor. Meantime, there is still no cure method and its recurrence rate is very high. Panobinostat is a histone deacetylase inhibitor (HDACi), which is used in MM treatment. This review summarizes the panobinostat used in MM treatment including its action mechanism against HDACi and its adverse reactions.

, authors=Xin-chi CHANG1, Na NI1, *, Xun-ting ZENG1, *, Cui-cui SHI1, Yu-han ZHAO1, Yan CHEN2, authorsList=Xin-chi CHANG, Na NI, Xun-ting ZENG, Cui-cui SHI, Yu-han ZHAO, Yan CHEN, authorCompany=null, correspAuthors=Na NI, Xun-ting ZENG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330127217486573787, articleId=1330127216941314265, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=多发性骨髓瘤治疗药物帕比司他的临床研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

多发性骨髓瘤(MM)是一种血液系统常见的恶性肿瘤,目前仍无治愈方法且复发率很高。帕比司他(panobinostat)是一种组蛋白去乙酰化酶抑制剂(HDACi),用于治疗MM。本文从HDACi的作用机制与帕比司他的不良反应总结帕比司他对MM的临床疗效。

, authors=常新驰1, 倪娜1, *, 曾训庭1, *, 石催催1, 赵宇晗1, 陈燕2, authorsList=常新驰, 倪娜, 曾训庭, 石催催, 赵宇晗, 陈燕, authorCompany=null, correspAuthors=倪娜, 曾训庭, authorNote=

常新驰,硕士研究生,研究方向:临床药学。

, correspAuthorsNote=
曾训庭,博士,副研究员,研究方向:临床药学,长期从事药物临床研究工作。
倪娜,硕士,研究方向:药物化学与临床药学,长期从事药物临床研究工作。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=iHomk+h0e6wSeAYrhqN5Xg==, magXml=gzfLBsLS6mVOZCD4PsNrIA==, pdfUrl=null, pdf=boHIBQ+KDg3J3eHlTMij5w==, pdfFileSize=932638, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=dzYHQaZuVX6Z0ff/FGijxg==, mapNumber=null, fund=null)}, authors=[Author(id=1330127217872449763, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330127218023444709, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127217872449763, language=EN, stringName=Xin-chi CHANG, firstName=Xin-chi, middleName=null, lastName=CHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127218090553574, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127217872449763, language=CN, stringName=常新驰, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio={"content":"

常新驰,硕士研究生,研究方向:临床药学。

"}, bioImg=null, bioContent=

常新驰,硕士研究生,研究方向:临床药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330127218166051048, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330127218249937130, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218166051048, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127218367377643, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218166051048, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330127218468040941, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330127218530955503, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218468040941, language=EN, stringName=Xun-ting ZENG, firstName=Xun-ting, middleName=null, lastName=ZENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127218585481456, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218468040941, language=CN, stringName=曾训庭, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330127218644201714, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330127218723893492, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218644201714, language=EN, stringName=Cui-cui SHI, firstName=Cui-cui, middleName=null, lastName=SHI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127218782613749, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218644201714, language=CN, stringName=石催催, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330127218845528311, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330127218921025785, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218845528311, language=EN, stringName=Yu-han ZHAO, firstName=Yu-han, middleName=null, lastName=ZHAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127218983940346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218845528311, language=CN, stringName=赵宇晗, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330127219046854908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330127219118158078, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127219046854908, language=EN, stringName=Yan CHEN, firstName=Yan, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127220732965120, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127219046854908, language=CN, stringName=陈燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217801146591, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=2., ext=[AuthorCompanyExt(id=1330127217809535200, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217801146591, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330127217817923809, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217801146591, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])])], keywords=[Keyword(id=1330127220858794241, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, language=EN, orderNo=1, keyword=multiple myeloma (MM)), Keyword(id=1330127220913320194, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, language=EN, orderNo=2, keyword=histone deacetylase inhibitors (HDACi)), Keyword(id=1330127220963651843, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, language=EN, orderNo=3, keyword=panobinostat), Keyword(id=1330127221026566404, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, language=CN, orderNo=1, keyword=多发性骨髓瘤(MM)), Keyword(id=1330127221089480965, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, language=CN, orderNo=2, keyword=组蛋白去乙酰化酶抑制剂(HDACi)), Keyword(id=1330127221194338566, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, language=CN, orderNo=3, keyword=帕比司他)], refs=[Reference(id=1330127221274030343, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=施淼颉, 刘澎. daratumumab治疗复发、难治性多发性骨髓瘤[J]. 世界临床药物, 2017, 38(3): 210-213., articleTitle=null, refAbstract=null), Reference(id=1330127221353722120, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=路瑾. 多发性骨髓瘤诊断标准的变迁及其对治疗的影响[J]. 中国肿瘤临床, 2014, 41(13): 819-822., articleTitle=null, refAbstract=null), Reference(id=1330127221412442377, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Adams J. The proteasome: a suitable antineoplastic target[J]. Nat Rev Cancer, 2004, 4(5): 349-360., articleTitle=null, refAbstract=null), Reference(id=1330127221483745546, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells[J]. Camcer Res, 2006, 66(1): 184-191., articleTitle=null, refAbstract=null), Reference(id=1330127221555048715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2005, 352(24): 2487-2498., articleTitle=null, refAbstract=null), Reference(id=1330127221622157580, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, et al. Histone deacetylase inhibitors: mechanism of action nd therapeutic use in cancer[J]. Clin Transl Oncol, 2008, 10(7): 395-398., articleTitle=null, refAbstract=null), Reference(id=1330127221680877837, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Weber DM, Graef T, Hussein M, et al. Phase Ⅰ trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2012, 12(5): 319-324., articleTitle=null, refAbstract=null), Reference(id=1330127221743792398, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed / refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase Ⅰ/Ⅱ trial[J]. J Clin Oncol, 2011, 29(32): 4243-4249., articleTitle=null, refAbstract=null), Reference(id=1330127221798318351, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Neri P, Tagliaferri P, Di Martino MT, et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor[J]. Br J Haematol, 2008, 143(4): 520-531., articleTitle=null, refAbstract=null), Reference(id=1330127221865427216, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhao B, He T. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer[J]. Oncol Rep, 2015, 33(1): 304-310., articleTitle=null, refAbstract=null), Reference(id=1330127221928341777, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Feng R, Ma H, Hassig CA, et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling[J]. Mol Cancer Ther, 2008, 7(6): 1494-1505., articleTitle=null, refAbstract=null), Reference(id=1330127221991256338, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Kitazoe K, Abe M, Hiasa M, et al. Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma[J]. Int J Hematol, 2009, 89(1): 45-57., articleTitle=null, refAbstract=null), Reference(id=1330127222045782291, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=蔡博, 柳柏林, 高春记. 组蛋白去乙酰化酶抑制剂在多发性骨髓瘤治疗中的研究进展[J]. 解放军医学院学报, 2013, 34(5): 529-530., articleTitle=null, refAbstract=null), Reference(id=1330127222104502548, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Maes K, Menu E, Van Valckenborgh E, et al. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma[J]. Cancers, 2013, 5(2): 430-461., articleTitle=null, refAbstract=null), Reference(id=1330127222167417109, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Atadja p. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges[J]. Cancer Lett, 2009, 280(2): 233-241., articleTitle=null, refAbstract=null), Reference(id=1330127222217748758, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that oVercomes drug resistance[J]. Cancer Res, 2006, 66(11): 5781-5789., articleTitle=null, refAbstract=null), Reference(id=1330127222276469015, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsedand refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1195-1206., articleTitle=null, refAbstract=null), Reference(id=1330127222335189272, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Richardson P, Roy A, Suddhasatta A, et al. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent[J]. Expert Rev Hematol, 2017, 10(10): 933-939., articleTitle=null, refAbstract=null), Reference(id=1330127222402298137, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma[J]. Blood, 2013, 122(14): 2331-2337., articleTitle=null, refAbstract=null), Reference(id=1330127222469407002, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Richardson PG, Laubach JP, Lonial S, et al. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma[J]. Expert Rev Anticancer Ther, 2015, 15(7): 737-748., articleTitle=null, refAbstract=null), Reference(id=1330127222565875995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Offidani M, Corvatta L, Liberati AM, et al. Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma[J]. Leuk Lymphoma, 2017, 9(11): 1-3., articleTitle=null, refAbstract=null), Reference(id=1330127222641373468, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Popat R, Brown SR, Flanagan L, et al. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiplemyeloma (MUK-six): a multicentre, open-label, phase 1/2 trial[J]. Lancet Haematol, 2016, 3(12): e572-e580., articleTitle=null, refAbstract=null), Reference(id=1330127222700093725, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Majer I, van de Wetering G, Polanyi Z, et al. Panobinostat plus bortezomib versus lenalidomide in patients with relapsed and/or refractory multiple myeloma: a matching-adjusted indirect treatment comparison of survival outcomesusing patient-level data[J]. Appl Health Econ Health Policy, 2017, 15(1): 45-55., articleTitle=null, refAbstract=null), Reference(id=1330127222771396894, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Baertsch MA, Hillengass J, Blocka J, et al. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice[J]. Hematol Oncol, 2017, doi: 10.1002/hon.2462., articleTitle=null, refAbstract=null), Reference(id=1330127222846894367, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Sharma S, Beck J, Mita M, et al. A phase Ⅰ dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors[J]. Invest New Drugs, 2013, 31(4): 974-985., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)]), AuthorCompany(id=1330127217801146591, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=2., ext=[AuthorCompanyExt(id=1330127217809535200, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217801146591, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330127217817923809, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217801146591, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2018.02.014, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2018.02.014, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2018.02.014, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2018.02.014, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1518192000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
多发性骨髓瘤治疗药物帕比司他的临床研究进展
常新驰 1 , 倪娜 1, * , 曾训庭 1, * , 石催催 1 , 赵宇晗 1 , 陈燕 2
世界临床药物 | 综述评论 2018,39(2): S9-S13
收起
收藏切换
世界临床药物 |综述评论 2018 , 39 (2) : S9 -S13
多发性骨髓瘤治疗药物帕比司他的临床研究进展
全屏
[Author(id=1330127217872449763, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330127218023444709, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127217872449763, language=EN, stringName=Xin-chi CHANG, firstName=Xin-chi, middleName=null, lastName=CHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127218090553574, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127217872449763, language=CN, stringName=常新驰, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio={"content":"

常新驰,硕士研究生,研究方向:临床药学。

"}, bioImg=null, bioContent=

常新驰,硕士研究生,研究方向:临床药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330127218166051048, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330127218249937130, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218166051048, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127218367377643, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218166051048, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330127218468040941, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330127218530955503, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218468040941, language=EN, stringName=Xun-ting ZENG, firstName=Xun-ting, middleName=null, lastName=ZENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127218585481456, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218468040941, language=CN, stringName=曾训庭, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330127218644201714, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330127218723893492, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218644201714, language=EN, stringName=Cui-cui SHI, firstName=Cui-cui, middleName=null, lastName=SHI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127218782613749, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218644201714, language=CN, stringName=石催催, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330127218845528311, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330127218921025785, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218845528311, language=EN, stringName=Yu-han ZHAO, firstName=Yu-han, middleName=null, lastName=ZHAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127218983940346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127218845528311, language=CN, stringName=赵宇晗, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217654345948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=1., ext=[AuthorCompanyExt(id=1330127217666928861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437), AuthorCompanyExt(id=1330127217671123166, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217654345948, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330127219046854908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330127219118158078, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127219046854908, language=EN, stringName=Yan CHEN, firstName=Yan, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330127220732965120, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, authorId=1330127219046854908, language=CN, stringName=陈燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330127217801146591, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, xref=2., ext=[AuthorCompanyExt(id=1330127217809535200, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217801146591, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330127217817923809, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330127216941314265, companyId=1330127217801146591, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])])]
常新驰1, 倪娜1, *, 曾训庭1, *, 石催催1, 赵宇晗1, 陈燕2
作者信息
  • 1.中国医药工业研究总院药物临床研究中心,上海 200437
  • 2.上海瀛科隆医药开发有限公司,上海 200437
通讯作者:
曾训庭,博士,副研究员,研究方向:临床药学,长期从事药物临床研究工作。
倪娜,硕士,研究方向:药物化学与临床药学,长期从事药物临床研究工作。
作者简介:

常新驰,硕士研究生,研究方向:临床药学。

Research progress of panobinostat on multiple myeloma treatment
Xin-chi CHANG1, Na NI1, *, Xun-ting ZENG1, *, Cui-cui SHI1, Yu-han ZHAO1, Yan CHEN2
Affiliations
  • 1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437
  • 2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China
出版时间: 2018-02-10 doi: 10.13683/j.wph.2018.02.014
文章导航
收藏切换

多发性骨髓瘤(MM)是一种血液系统常见的恶性肿瘤,目前仍无治愈方法且复发率很高。帕比司他(panobinostat)是一种组蛋白去乙酰化酶抑制剂(HDACi),用于治疗MM。本文从HDACi的作用机制与帕比司他的不良反应总结帕比司他对MM的临床疗效。

多发性骨髓瘤(MM)  /  组蛋白去乙酰化酶抑制剂(HDACi)  /  帕比司他

Multiple myeloma (MM) is a common malignant blood tumor. Meantime, there is still no cure method and its recurrence rate is very high. Panobinostat is a histone deacetylase inhibitor (HDACi), which is used in MM treatment. This review summarizes the panobinostat used in MM treatment including its action mechanism against HDACi and its adverse reactions.

multiple myeloma (MM)  /  histone deacetylase inhibitors (HDACi)  /  panobinostat
常新驰, 倪娜, 曾训庭, 石催催, 赵宇晗, 陈燕. 多发性骨髓瘤治疗药物帕比司他的临床研究进展. 世界临床药物, 2018 , 39 (2) : S9 -S13 . DOI: 10.13683/j.wph.2018.02.014
Xin-chi CHANG, Na NI, Xun-ting ZENG, Cui-cui SHI, Yu-han ZHAO, Yan CHEN. Research progress of panobinostat on multiple myeloma treatment[J]. World Clinical Drug, 2018 , 39 (2) : S9 -S13 . DOI: 10.13683/j.wph.2018.02.014

参考文献 引证文献
排序方式:
[1]
施淼颉, 刘澎. daratumumab治疗复发、难治性多发性骨髓瘤[J]. 世界临床药物, 2017, 38(3): 210-213.
[2]
路瑾. 多发性骨髓瘤诊断标准的变迁及其对治疗的影响[J]. 中国肿瘤临床, 2014, 41(13): 819-822.
[3]
Adams J. The proteasome: a suitable antineoplastic target[J]. Nat Rev Cancer, 2004, 4(5): 349-360.
[4]
Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells[J]. Camcer Res, 2006, 66(1): 184-191.
[5]
Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2005, 352(24): 2487-2498.
[6]
Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, et al. Histone deacetylase inhibitors: mechanism of action nd therapeutic use in cancer[J]. Clin Transl Oncol, 2008, 10(7): 395-398.
[7]
Weber DM, Graef T, Hussein M, et al. Phase Ⅰ trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2012, 12(5): 319-324.
[8]
Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed / refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase Ⅰ/Ⅱ trial[J]. J Clin Oncol, 2011, 29(32): 4243-4249.
[9]
Neri P, Tagliaferri P, Di Martino MT, et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor[J]. Br J Haematol, 2008, 143(4): 520-531.
[10]
Zhao B, He T. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer[J]. Oncol Rep, 2015, 33(1): 304-310.
[11]
Feng R, Ma H, Hassig CA, et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling[J]. Mol Cancer Ther, 2008, 7(6): 1494-1505.
[12]
Kitazoe K, Abe M, Hiasa M, et al. Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma[J]. Int J Hematol, 2009, 89(1): 45-57.
[13]
蔡博, 柳柏林, 高春记. 组蛋白去乙酰化酶抑制剂在多发性骨髓瘤治疗中的研究进展[J]. 解放军医学院学报, 2013, 34(5): 529-530.
[14]
Maes K, Menu E, Van Valckenborgh E, et al. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma[J]. Cancers, 2013, 5(2): 430-461.
[15]
Atadja p. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges[J]. Cancer Lett, 2009, 280(2): 233-241.
[16]
Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that oVercomes drug resistance[J]. Cancer Res, 2006, 66(11): 5781-5789.
[17]
San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsedand refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1195-1206.
[18]
Richardson P, Roy A, Suddhasatta A, et al. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent[J]. Expert Rev Hematol, 2017, 10(10): 933-939.
[19]
Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma[J]. Blood, 2013, 122(14): 2331-2337.
[20]
Richardson PG, Laubach JP, Lonial S, et al. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma[J]. Expert Rev Anticancer Ther, 2015, 15(7): 737-748.
[21]
Offidani M, Corvatta L, Liberati AM, et al. Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma[J]. Leuk Lymphoma, 2017, 9(11): 1-3.
[22]
Popat R, Brown SR, Flanagan L, et al. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiplemyeloma (MUK-six): a multicentre, open-label, phase 1/2 trial[J]. Lancet Haematol, 2016, 3(12): e572-e580.
[23]
Majer I, van de Wetering G, Polanyi Z, et al. Panobinostat plus bortezomib versus lenalidomide in patients with relapsed and/or refractory multiple myeloma: a matching-adjusted indirect treatment comparison of survival outcomesusing patient-level data[J]. Appl Health Econ Health Policy, 2017, 15(1): 45-55.
[24]
Baertsch MA, Hillengass J, Blocka J, et al. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice[J]. Hematol Oncol, 2017, doi: 10.1002/hon.2462.
[25]
Sharma S, Beck J, Mita M, et al. A phase Ⅰ dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors[J]. Invest New Drugs, 2013, 31(4): 974-985.
2018年第39卷第2期
13
4
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2018.02.014
  • 接收时间:2017-11-09
  • 首发时间:2026-11-19
  • 出版时间:2018-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2017-11-09
  • 修回日期:2017-12-16
基金
作者信息
    1.中国医药工业研究总院药物临床研究中心,上海 200437
    2.上海瀛科隆医药开发有限公司,上海 200437

通讯作者:

曾训庭,博士,副研究员,研究方向:临床药学,长期从事药物临床研究工作。
倪娜,硕士,研究方向:药物化学与临床药学,长期从事药物临床研究工作。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2018.02.014
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏